Bernd Schmidt
Chief Tech/Sci/R&D Officer bei SENSORION
Profil
Bernd Schmidt is currently the Chief Technical Officer at Sensorion SA since 2023.
Prior to this, he worked as the Vice President-Product Delivery at Quell Therapeutics Ltd.
Mr. Schmidt is a graduate of Friedrich-Alexander University of Erlangen-Nuremberg.
Aktive Positionen von Bernd Schmidt
Unternehmen | Position | Beginn |
---|---|---|
SENSORION | Chief Tech/Sci/R&D Officer | 11.12.2023 |
Ehemalige bekannte Positionen von Bernd Schmidt
Unternehmen | Position | Ende |
---|---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | - |
Ausbildung von Bernd Schmidt
Friedrich-Alexander University of Erlangen-Nuremberg | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SENSORION | Health Technology |
Private Unternehmen | 1 |
---|---|
Quell Therapeutics Ltd.
Quell Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Quell Therapeutics Ltd. is a London-based biotechnology company, which develops immune cell therapies to target transplant rejection, autoimmune and inflammatory diseases. It develops engineered T regulatory cell therapies for a variety of non-cancer targets. The company was founded on March 19, 2019 and is headquartered in London, the United Kingdom. | Health Technology |